Pirfenidone News and Research

RSS

Human senescent fibroblasts trigger fibrogenic reaction in the lungs of immunodeficient mice

A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 14, entitled, "Human senescent fibroblasts trigger progressive lung fibrosis in mice."

31 Jul 2023

3D-printed vaginal ovules offer promising treatment for endometriosis

3D-printed vaginal ovules offer controlled release and targeted treatment, showing promise for conditions like endometriosis.

20 Jun 2023

Understanding post-COVID interstitial lung disease: Causes, treatment options

After being hospitalized for three months with COVID-19 and double pneumonia in 2020, Houston police officer Hito Bazan awoke one morning to discover that he couldn't talk, eat, walk, or most importantly, breathe. Bazan was diagnosed with interstitial lung disease (ILD) known as pulmonary fibrosis (PF).

27 Apr 2023

3D cell culture system tests how inhibiting fibroblast activities can help treat lung cancer

Fibroblasts build and maintain the extracellular matrix, or physical scaffolding for cells, in the connective tissues within the body.

28 Mar 2023

Anti-fibrotics found to be safe, effective for interstitial lung disease in patients with rheumatoid arthritis

For the first time, researchers have shown that a class of anti-fibrotic drugs slows the progression of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA).

22 Sep 2022

Y chromosome loss in men can lead to deadly heart failure, research shows

The loss of the male sex chromosome as many men age causes the heart muscle to scar and can lead to deadly heart failure, new research from the University of Virginia School of Medicine shows.

14 Jul 2022

Pirfenidone significantly reduces a marker of heart muscle scarring

Patients with heart failure with preserved ejection fraction who took the antifibrotic drug pirfenidone saw a significant reduction in a marker of heart muscle scarring compared with patients who received a placebo, based on findings from an early-phase trial presented at the American College of Cardiology's 70th Annual Scientific Session.

18 May 2021

Powerful treatment for IPF stops dangerous scar formation in mouse lungs

A pre-clinical study led by scientists at Cincinnati Children's demonstrates that in mice the drug barasertib reverses the activation of fibroblasts that cause dangerous scar tissue to build up in the lungs of people with idiopathic pulmonary fibrosis (IPF).

6 Aug 2020

Cost of ‘repurposing’ existing drugs to treat COVID-19

The paper looks at repurposed drugs that might demonstrate efficacy against COVID-19, and if they could be manufactured profitably at very low costs to ensure affordable access to vital treatments for COVID-19 at low prices globally.

13 Apr 2020

New lung tissue-on-a-chip system offers rapid testing of potential anti-fibrotic treatments

Pulmonary fibrosis is one of the most common and serious types of lung disease. Now NIBIB-funded researchers have developed an in vitro lung tissue-on-a-chip system that mimics lung fibrosis, offering rapid testing of potential new anti-fibrotic treatments.

28 Aug 2018

Researchers identify culprit that spurs damaging inflammation following heart attack

Scientists have zeroed in on a culprit that spurs damaging inflammation in the heart following a heart attack. The guilty party is a type of immune cell that tries to heal the injured heart but instead triggers inflammation that leads to even more damage.

8 Jun 2018

Lung-on-a-chip technology could streamline drug-testing for pulmonary fibrosis

Developing new medicines to treat pulmonary fibrosis, one of the most common and serious forms of lung disease, is not easy.

25 May 2018

Pulmospheres could serve as personalized, predictive model for assessing effect of IPF drugs

Pulmospheres, three dimensional multicellular spheroids composed of lung cells from individual patients, were shown to be effective in predicting the efficacy of medications for idiopathic pulmonary fibrosis, according to findings from University of Alabama at Birmingham scientists presented today in JCI Insight, a journal of the American Society for Clinical Investigation.

27 Jan 2017

2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

This year's prestigious Canadian Prix Galien for Innovative Product Award has been presented to Esbriet (pirfenidone), a medicine used to treat idiopathic pulmonary fibrosis (IPF). It is the only medication approved in Canada with a specific IPF indication and is approved for mild to moderate IPF in adults.

21 Nov 2014

Viewpoints: Medicare no longer 'busting' the budget; a 'nightmare' trying to get coverage in D.C.

You're looking at the biggest story involving the federal budget and a crucial one for the future of the American economy. Every year for the last six years in a row, the Congressional Budget Office has reduced its estimate for how much the federal government will need to spend on Medicare in coming years.

29 Aug 2014

FDA grants orphan-drug designation to Genoa's pirfenidone for treatment of IPF disease

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, today announced the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to Genoa for the use of pirfenidone in their lead program - inhaled GP-101 for the treatment of IPF.

5 Aug 2014

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Researchers in separate clinical trials found two drugs slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease with no effective treatment or cure, and for which there is currently no therapy approved by the Food and Drug Administration.

19 May 2014

First Edition: May 19, 2014

Today's headlines include a report about federal health care subsidies and an update on states small business health exchanges.

19 May 2014

PFF Patient Communication Center: The destination for latest disease education information

The newly launched Pulmonary Fibrosis Foundation Patient Communication Center (PCC) has become the destination for the most up-to-date information for the pulmonary fibrosis community. The PCC now has information about the Expanded Access Program (EAP) for pirfenidone.

16 May 2014

Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced today additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF).

21 Apr 2014